BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Leads Biolabs Doses First Patient In Phase II Trial Of LBL-034, China’s First Potential GPRC5D-Targeted T-Cell Engager

Nanjing Leads Biolabs Co., Ltd. announced the first patient has been successfully dosed in the Phase Ⅱ trial of LBL-034 (GPRC5D/CD3 BsAb) following...

August 26, 2025 | News

Antengene Reports Strong H1 2025 Results with Breakthrough Therapy Designation for ATG-022 and Robust Pipeline Progress

The Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate) demonstrated promising results, showing robust clinical efficacy and a fav...

August 25, 2025 | Company results

China’s Bio-Thera and Europe’s STADA Expand Biosimilars Alliance to Include Tocilizumab

Bio-Thera and STADA agree to extend their biosimilars alliance to cover tocilizumab, a targeted immunomodulatory monoclonal antibody directed against the...

August 25, 2025 | News

BioDlink Secures Indonesian Approval for Bevacizumab, Accelerating ASEAN and Global Expansion

BioDlink announced that its Bevacizumab Injection has obtained marketing authorization from Indonesia's National Agency of Drug and Food Con...

August 22, 2025 | News

Asia-Pacific Leads the Charge: Latest Global BioSupplier Technologies of 2025

The first eight months of 2025 have been transformative for biosupplier technologies worldwide. From innovative lab reagents and biomaterials to ad...

August 22, 2025 | Analysis

RemeGen and Santen Form Strategic Alliance on RC28-E for Asia and Greater China

RemeGen Co., a leading Chinese biopharmaceutical company, announced that it has entered into an agreement with Santen Pharmaceutical (China) Co., Ltd. ("Sa...

August 20, 2025 | News

WuXi Biologics Posts Robust H1 2025 Results with Margin Expansion and Record Project Wins

Revenue increased by 16.1% YoY to RMB 9,953.2 million; revenue growth from continuing operations was 20.2% IFRS Gross profit margin expanded b...

August 20, 2025 | Company results

Mabwell Secures FDA IND Clearance for CDH17-Targeting ADC 7MW4911 in Advanced GI Cancers

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D cod...

August 20, 2025 | News

Datasea Launches Breakthrough Acoustic–AI Healthcare Innovation, Targeting $190 Billion Global Market by 2030

DTSS' Acoustic innovation Addresses the Healthcare Application Market Projected to Exceed $100 Billion in China and Approach $90 B...

August 19, 2025 | News

WuXi XDC Delivers 62% Revenue Growth and Record Project Momentum in H1 2025

- Revenue increased by 62.2% YoY to RMB 2,701 million - Gross profit surged by 82.2% YoY to RMB 975 million, with i...

August 19, 2025 | Company results

Everest Medicines’ Etrasimod (VELSIPITY®) Receives Strong Recommendation in Updated ACG Clinical Guideline for Ulcerative Colitis

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...

August 18, 2025 | News